Analyst Price Targets — MDRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 19, 2024 2:09 am | George Hill | Deutsche Bank | $10.00 | $8.20 | StreetInsider | Deutsche Bank Downgrades Veradigm Inc (MDRX) to Hold |
| February 1, 2023 5:20 am | — | Piper Sandler | $18.50 | $17.91 | Benzinga | Piper Sandler Downgrades Veradigm to Neutral, Raises Price Target to $18.5 |
| November 18, 2022 7:56 am | — | J.P. Morgan | $20.00 | $18.72 | Benzinga | JP Morgan Maintains Underweight on Allscripts Healthcare, Raises Price Target to $20 |
| June 10, 2022 7:18 am | — | Piper Sandler | $17.00 | $16.92 | Benzinga | Piper Sandler Maintains Neutral on Allscripts Healthcare, Lowers Price Target to $17 |
| May 6, 2022 8:40 am | — | Piper Sandler | $19.00 | $19.02 | Benzinga | Piper Sandler Maintains Neutral on Allscripts Healthcare, Lowers Price Target to $19 |
Latest News for MDRX
Veradigm Inc. (MDRX) Discusses Progress on SEC Filings, Relisting Efforts and Strategic Update Transcript
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today the filing of its comprehensive Annual Report on Form 10-K for the years ended December 31, 2023 and 2024 (the “2023 and 2024 Form 10-K”) with the Securities and Exchange Commission (“SEC”). “In our previous shareholder update, I framed a critical must-do to get…
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today released findings from a nationally distributed survey of 360 independent practice leaders, conducted in March 2026. The survey respondents resolved to remain independent and are counting on technology as a critical lever to drive practice performance. Technology Is…
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced that it has been recognized by KLAS in the 2026 Points of Light Award program for a collaborative initiative that embedded payer-derived social determinants of health (SDOH) data directly into provider EHR workflows. The recognition, awarded as part of the KLAS K2…
PUNE, India--(BUSINESS WIRE)--Veradigm® India Private Limited, the India subsidiary of Veradigm (OTCMKTS: MDRX), a US-based leader in clinical and revenue cycle solutions for independent practices, today announced a major expansion of its Pune operations, doubling its office capacity and adding a new managing director. This milestone marks a significant chapter in Veradigm's growth journey, reflecting the company's…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.